Menu

Another Dengue Vaccine Shows Promise

Researchers demonstrate the success of a new combination vaccine in clinical trials.

Mar 16, 2016
Catherine Offord

Map showing regions populated by the virus’ vector, the Aedes aegypti mosquito (red and orange), and regions with an active epidemic of dengue fever (red only).WIKIMEDIA, PERCHERIEDengue is the most common mosquito-transmitted virus in the world and, in severe infections, can cause potentially life-threatening fevers. Currently, only one vaccine has been approved, but now a new, attenuated vaccine is performing well in randomized, double-blind trials, according to a study published today (March 16) in Science Translational Medicine.

“We developed and tested a human challenge model of dengue virus infection,” study coauthor Steven Whitehead of the National Institute of Allergy and Infectious Diseases told reporters during a press briefing. “The really remarkable success of this endeavor is now the subject of [this paper].”

There are four serotypes of the flavivirus (DEN-1 up to DEN-4) that can cause disease. “A useful vaccine really needs to protect against all four of them at the same time,” explained Whitehead in the statement. Using recombinant DNA technology, the researchers created various candidate vaccines for each dengue type that were tested individually in clinical trials to confirm their ability to stimulate an immune response. The researchers then mixed the best-performing vaccines for each serotype into a tetravalent vaccine—“a kind of four-in-one combination, if you will,” added Whitehead.

The researchers administered either this vaccine or a placebo to a group of 48 volunteers. After six months, they “challenged” those volunteers with a weakened strain of DEN-2, which causes only a mild infection, a slight rash, and a dip in white blood cell count. While all volunteers who had previously received the attenuated vaccine were protected against DEN-2, every volunteer in the placebo group became infected. Preliminary results suggest similar results with DEN-3, study coauthor Anna Durbin of John Hopkins Bloomberg School of Public Health told reporters, adding that the team planned to test safe versions of DEN-1 and DEN-4 as well.

Previously, a lack of human challenge studies was “one of the things that has made the development of dengue vaccines very difficult,” Duane Gubler of the Duke-NUS Medical School in Singapore who was not involved in the work told Nature.

The vaccine is now being tested in Phase 3 trials with much larger numbers of participants, Durbin told reporters, adding that the experience gained in the development of this human challenge model may also potentially be translatable into models for other flaviviruses, such as Zika.

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Application of TruBIOME™ to Increase Mouse Model Reproducibility
Application of TruBIOME™ to Increase Mouse Model Reproducibility
With this application note from Taconic, learn about the effects of the microbiome on reproducibility and predictability and how TruBIOME™ helps researchers generate custom microbiota mouse models!
Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.